Conference Track

New Developments in the Management of Chronic Hepatitis B

Source: CCO Official Conference Coverage of the Shanghai-Hong Kong International Liver Congress 2006

Capsule Summaries

2-Year Adefovir Treatment Appears Safe, Effective in HBeAg-Positive Chinese Patients Chronically Infected With HBV
HBeAg Levels at Baseline, During Treatment With Peginterferon Alfa-2a Can Predict Failure to Seroconvert in HBeAg-Positive Patients With Chronic Hepatitis B
No Entecavir Resistance After 2 Years of Treatment in Nucleoside-Naive Chronic Hepatitis B
GLOBE: Telbivudine Superior to Lamivudine Across Nearly All Patient Subgroups at 1 Year
48-Week Clevudine Regimen Appears Effective, Safe in Nucleoside-Naive Patients With HBeAg-Positive Chronic Hepatitis B
Peginterferon alfa-2a Produces Durable Responses in Asian Patients With HBeAg-Positive Chronic Hepatitis B
Favorable 24-Week Sustained Response Rate for HBeAg-Negative Asian Patients Following Peginterferon alfa-2a Treatment
Entecavir Demonstrates Superior Virologic, Biochemical Efficacy vs Lamivudine at Year 2 in HBeAg-Positive Patients
Entecavir Superior to Lamivudine in Nucleoside-Naive Chinese Patients With Chronic Hepatitis B
Telbivudine Superior to Lamivudine in Chinese Adults With Chronic Hepatitis B
Antibody Against HBV Protein X a Potential Marker of Progression to Cirrhosis, HCC in Individuals With Chronic Hepatitis B
Dendritic Cells Transduced With HBV Genes Activate Antigen-Specific Cytotoxic T Lymphocyte Responses In Vitro
RNA Interference Reduces In Vitro Tumorigenicity of HBx-Transformed Hepatic Cell Lines

Expert Analysis

New Developments in the Management of Chronic Hepatitis B

CME Program Director: George K. K. Lau, MD

Faculty:

Nancy W.Y. Leung, MD
Anna S. F. Lok, MD
Guang-bi Yao, MD

Learning Objectives

Upon completion of this activity, participants should be able to:

Discuss recent clinical trial data regarding the use of antiretroviral drugs in patients with hepatitis B infection
Identify which patients with hepatitis B infection are likely to benefit from specific therapeutic modalities
Describe the use and effects of peginterferon treatment in Asian patients with hepatitis B infection

CREDIT INFORMATION

Release Date: 05/17/06

Expiration Date: 05/16/07

Physicians: maximum of 1.25 AMA PRA Category 1 Credits™

Status: Please log in to view status

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.